5,794 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,794 shares of the medical equipment provider’s stock, valued at approximately $571,000.

Other large investors have also bought and sold shares of the company. Legacy Wealth Asset Management LLC raised its holdings in Zimmer Biomet by 2.3% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock worth $460,000 after acquiring an additional 106 shares during the last quarter. Global Retirement Partners LLC lifted its holdings in shares of Zimmer Biomet by 7.0% during the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 111 shares in the last quarter. Cullen Frost Bankers Inc. boosted its position in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 116 shares during the last quarter. Generali Asset Management SPA SGR increased its holdings in Zimmer Biomet by 0.9% in the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after buying an additional 122 shares in the last quarter. Finally, Brookstone Capital Management increased its holdings in Zimmer Biomet by 1.3% in the 3rd quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock worth $921,000 after buying an additional 123 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. BTIG Research restated a “buy” rating and set a $112.00 target price on shares of Zimmer Biomet in a research note on Tuesday, February 10th. Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. Barclays decreased their price objective on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a report on Thursday, February 12th. Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $100.00 target price (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Price Performance

NYSE ZBH opened at $91.78 on Wednesday. The company has a 50-day moving average price of $92.21 and a 200-day moving average price of $95.41. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $114.44. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $17.96 billion, a P/E ratio of 25.93, a PEG ratio of 1.91 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter last year, the firm posted $2.31 earnings per share. The firm’s revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is presently 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.